Michael Saag American AIDS researcher
Saag, Michael S.
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
Michael Saag
Saag, Michael
Saag, Michael S., 1955-
Saag, Michael (Michael S.)
VIAF ID: 27392832 (Personal)
Permalink: http://viaf.org/viaf/27392832
Preferred Forms
-
100 0 _
‡a
Michael Saag
-
100 0 _
‡a
Michael Saag
‡c
American AIDS researcher
-
200 _ |
‡a
Saag
‡b
Michael
-
100 1 _
‡a
Saag, Michael S.
(sparse)
-
100 1 _
‡a
Saag, Michael S.
-
100 1 _
‡a
Saag, Michael S.
-
100 1 _ ‡a Saag, Michael S.
-
100 1 _ ‡a Saag, Michael S.
-
100 1 _ ‡a Saag, Michael S.
-
100 1 _
‡a
Saag, Michael S.
-
100 1 _ ‡a Saag, Michael S.
-
100 1 _ ‡a Saag, Michael S.
-
100 1 _ ‡a Saag, Michael S., ‡d 1955-
-
100 1 _ ‡a Saag, Michael ‡q (Michael S.) (sparse)
4xx's: Alternate Name Forms (11)
Works
| Title | Sources |
|---|---|
| AIDS therapy |
|
| Emerging problems in the management of systemic mycotic infections, c1993: |
|
| Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus |
|
| Enhanced personal contact with HIV patients improves retention in primary care: a randomized trial in 6 US HIV clinics |
|
| Estimating a set of mortality risk functions with multiple contributing causes of death |
|
| Ethnic variations in the prevalence of metabolic bone disease among HIV-positive patients with lipodystrophy |
|
| Evaluation of distinct blood lymphocyte populations in human immunodeficiency virus type 1-infected subjects in the absence or presence of effective therapy |
|
| Evaluation of the single-item self-rating adherence scale for use in routine clinical care of people living with HIV. |
|
| Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068 |
|
| Evolution of HIV-1 drug resistance after virological failure of first-line antiretroviral therapy in Lusaka, Zambia |
|
| Evolving understanding of the immunopathogenesis of HIV. |
|
| Factors associated with delayed hepatitis B viral suppression on tenofovir among patients coinfected with HBV-HIV in the CNICS cohort |
|
| Factors Associated with Missed Psychiatry Visits in an Urban HIV Clinic. |
|
| Failure to Establish HIV Care: Characterizing the "No Show" Phenomenon |
|
| Fructosamine and Hemoglobin A1c Correlations in HIV-Infected Adults in Routine Clinical Care: Impact of Anemia and Albumin Levels |
|
| Gastrointestinal complications of HIV infection: changing priorities in the HAART era. |
|
| Gender differences in discontinuation of antiretroviral treatment regimens. |
|
| Genes linked to energy metabolism and immunoregulatory mechanisms are associated with subcutaneous adipose tissue distribution in HIV-infected men. |
|
| Genetic architecture of cardiometabolic risks in people living with HIV |
|
| Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection |
|
| Glycan Positioning Impacts HIV-1 Env Glycan-Shield Density, Function, and Recognition by Antibodies |
|
| Health care system and policy factors influencing engagement in HIV medical care: piecing together the fragments of a fractured health care delivery system |
|
| Health-related quality of life in the gender, race, and clinical experience trial |
|
| Hepatitis C Among High-Risk Alabamians: Disease Burden and Screening Effectiveness |
|
| High-Level Viremia in Adults and Children Infected with Human Immunodeficiency Virus: Relation to Disease Stage and CD4+ Lymphocyte Levels |
|
| High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR |
|
| High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients |
|
| Hit-and-run stimulation: a novel concept to reactivate latent HIV-1 infection without cytokine gene induction |
|
| HIV-1 and HAART: a time to cure, a time to kill |
|
| HIV-1 sequence subtype D in the United States. |
|
| HIV/AIDS |
|
| A molecular clone of HIV-1 tropic and cytopathic for human and chimpanzee lymphocytes. |
|
| A multi-investigator/institutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128. |
|
| An open-label safety study of enfuvirtide injection with a needle-free injection device or needle/syringe: the Biojector 2000 Open-label Safety Study (BOSS). |
|
| Positive, 2014: |
|
| Positive : one doctor's personal encounters with death, life, and the US healthcare system |
|
| Przewodnik terapii przeciwdrobnoustrojowej Sanforda 2019 : 50-lecie 1969-2019 |
|
| Przewodnik terapii wirusowych zapaleń wątroby Sanforda 2016-2017 |
|
| Racial disparities in HIV virologic failure: do missed visits matter? |
|
| Sanfodo kansensho chiryo gaido : Nihongoban. |
|
| Sanford guide to antimicrobial therapy |
|
| A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group |
|
| Toward a definition of HIV expertise: a survey of experienced HIV physicians |
|
| Transmitted drug resistance in the CFAR network of integrated clinical systems cohort: prevalence and effects on pre-therapy CD4 and viral load |
|
| Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel |
|
| Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients. |
|
| Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Acquired Immunodeficiency Syndrome Clinical Trials Group and Mycoses Study Group. |
|
| Treatment of HIV infection: the antiretroviral nucleoside analogues. Nucleoside analogues: adverse effects |
|
| Treatment response in acute/early infection versus advanced AIDS: equivalent first and second phases of HIV RNA decline |
|
| Treatment with recombinant growth hormone is associated with modest improvement in CD4 lymphocyte reconstitution in HIV-infected persons on antiretroviral therapy: results of ACTG A5174 |
|
| Trends in AIDS-Defining and Non--AIDS-Defining Malignancies among HIV-Infected Patients: 1989-2002 |
|
| Trends in antiretroviral therapy prescription, durability and modification: new drugs, more changes, but less failure |
|
| TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir |
|
| Types of Myocardial Infarction Among Human Immunodeficiency Virus-Infected Individuals in the United States |
|
| Unanticipated Effects of New Drug Availability on Antiretroviral Durability: Implications for Comparative Effectiveness Research. |
|
| Uncompensated medical provider costs associated with prior authorization for prescription medications in an HIV clinic. |
|
| Underutilization of aspirin for primary prevention of cardiovascular disease among HIV-infected patients |
|
| Underutilization of the AIDS Drug Assistance Program: associated factors and policy implications. |
|
| Unrecognized chronic hepatitis C virus infection among baby boomers in the emergency department. |
|
| Unusual thromboses associated with protein S deficiency in patients with acquired immunodeficiency syndrome: case reports and review of the literature |
|
| Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy |
|
| Use of virologic markers in clinical practice |
|
| Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy |
|
| Using Patient Perspectives to Inform the Development of a Behavioral Intervention for Chronic Pain in Patients with HIV: A Qualitative Study. |
|
| Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal |
|
| Viral dynamics in primary HIV-1 infection |
|
| Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy |
|
| Virologic and immunologic response to HAART, by age and regimen class |
|
| Virologic Failure Among People Living With HIV Initiating Dolutegravir-Based Versus Other Recommended Regimens in Real-World Clinical Care Settings |
|
| Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) trials |
|
| Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients |
|
| Weight gain following antiretroviral therapy (ART) initiation in ART-naïve people living with HIV in the current treatment era |
|
| What to do when zidovudine fails |
|
| What's All This Fuss I hear about Viral "Blips"? |
|
| When to Monitor CD4 Cell Count and HIV RNA to Reduce Mortality and AIDS-Defining Illness in Virologically Suppressed HIV-Positive Persons on Antiretroviral Therapy in High-Income Countries: A Prospective Observational Study |
|
| When to start: as soon as possible. |
|
| Which policy to ADAP-T: waiting lists or waiting lines? |
|
| Wirksamkeit, Sicherheit und Pharmakokinetik der einmal täglich einzunehmenden Saquinavir-Weich-Gelatin-Kapsel/Ritonavir bei antiretroviral-naiven, HIV-infizierten Patienten. |
|
| サンフォード感染症治療ガイド : 日本語版. |
|
